Krystal Biotech (KRYS) Total Non-Current Liabilities (2018 - 2026)
Krystal Biotech (KRYS) posted quarterly Total Non-Current Liabilities of $134.4 million for Q2 2026, up 41.6% year-over-year from $94.9 million in Q2 2025, and up 16.79% on a QoQ basis from $115.1 million in Q1 2026.
Krystal Biotech (KRYS) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Krystal Biotech has reported Total Non-Current Liabilities for 5 years, with the latest figure at $134.4 million in Q2 2026.
- Total Non-Current Liabilities for Q2 2026 came in at $134.4 million, up 41.6% year-over-year; the trailing twelve-month figure through Jun 2026 was $134.4 million (up 41.6% YoY), and the FY2025 annual result was $110.5 million, up 2.29% from the prior year.
- Total Non-Current Liabilities climbed to $134.4 million in Q2 2026, from $115.1 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $134.4 million in Q2 2026 and troughed at $39.7 million in Q4 2023.
- A 4-year average of $96.3 million and a median of $97.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The widest annual swing landed in 2024, when Total Non-Current Liabilities jumped 172.04%; it then advanced 2.29% in 2025.
- A 4-year view of Total Non-Current Liabilities shows it stood at $39.7 million in 2023, then jumped by 172.04% to $108.0 million in 2024, then advanced by 2.29% to $110.5 million in 2025, then advanced by 21.66% to $134.4 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $134.4 million in Q2 2026, $115.1 million in Q1 2026, and $110.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 134.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134.44 Mn |
| Mar 31, 2026 | 115.14 Mn |
| Dec 31, 2025 | 110.51 Mn |
| Sep 30, 2025 | 99.12 Mn |
| Jun 30, 2025 | 94.96 Mn |
| Mar 31, 2025 | 87.74 Mn |
| Dec 31, 2024 | 108.04 Mn |
| Sep 30, 2024 | 95.71 Mn |
| Jun 30, 2024 | 78.18 Mn |
| Dec 31, 2023 | 39.71 Mn |
| Dec 31, 2018 | 2.60 Mn |
| Sep 30, 2018 | 1.92 Mn |